Biotech startup Bugworks raises $18 Mn from Lightrock, others to fight off drug-resistant bacteria
Shortpedia
Content Team
Image Credit: Inc42
Bengaluru-based biotech startup Bugworks Research has announced a $18 Mn Series B1 round, which was led by Lightrock India, with participation from existing investors, including 3one4 Capital. Bugworks will look to leverage the funds to support the clinical development of BWC0977, a novel broad spectrum antibacterial agent. The company will look to accelerate clinical trials on AMR and bolster its immuno oncology program.
